Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epirubicin for the Treatment of Sepsis and Septic Shock
2021-002300-12Phase 2Active
- Sponsor
- Friedrich Schiller University Jena
- Start
- Jul 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of epirubicin in sepsis, septic shock, bacterial disease and 1 more, sponsored by Friedrich Schiller University Jena. Primary endpoint: Myelotoxicity until day 14. Started Jul 2021; status: active.
02
Drugs
epirubicin
03
Conditions
sepsisseptic shockbacterial diseasemycoses
Beyond the preview
Go deeper on 2021-002300-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002300-12.